3-[(5-chloro-2-[[(iodomethyl)oxy]carbonyloxy]phenyl)methyl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one | 233676-41-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: 3-[(5-chloro-2-[[(iodomethyl)oxy]carbonyloxy]phenyl)methyl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one
• 英文别名: [4-Chloro-2-[[2-oxo-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-3-yl]methyl]phenyl] iodomethyl carbonate
• CAS: 233676-41-0
• 化学式: C₁₈H₁₁ClF₃IN₂O₅
• 分子量: 554.648
• InChiKey: GEYUBSAOTHWUDA-UHFFFAOYSA-N

物化性质

• 沸点：
  537.3±60.0 °C(Predicted)
• 密度：
  1.80±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  77.4
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  3-[(5-chloro-2-[[(iodomethyl)oxy]carbonyloxy]phenyl)methyl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one 在 platinum(IV) oxide 氢气 作用下， 以 乙酸乙酯 、 苯 为溶剂， 生成 3-[(5-Chloro-2-[[[(phosphonooxy)methyl]oxy]carbonyloxy]-phenyl)methyl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one
  参考文献：
  名称：

  Synthesis of water-Soluble prodrugs of BMS-191011: A maxi-K channel opener targeted for post-stroke neuroprotection

  摘要：

  A variety of water-soluble prodrugs of BMS-191011 was synthesized and evaluated for solution state stability and rate of conversion to BMS-191011 in rat and human plasma. The deoxycarnitine ester prodrug (11c) was selected for clinical evaluation based on its superior chemical stability, crystallinity and cleavage to BMS-191011 in human plasma. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00296-8
• 作为产物：
  描述：

  3-(5-氯-2-羟基苄基)-5-(4-(三氟甲基)苯基)-1,3,4-噁二唑-2(3h)-酮 在 吡啶 、 sodium iodide 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 生成 3-[(5-chloro-2-[[(iodomethyl)oxy]carbonyloxy]phenyl)methyl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one
  参考文献：
  名称：

  Synthesis of water-Soluble prodrugs of BMS-191011: A maxi-K channel opener targeted for post-stroke neuroprotection

  摘要：

  A variety of water-soluble prodrugs of BMS-191011 was synthesized and evaluated for solution state stability and rate of conversion to BMS-191011 in rat and human plasma. The deoxycarnitine ester prodrug (11c) was selected for clinical evaluation based on its superior chemical stability, crystallinity and cleavage to BMS-191011 in human plasma. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00296-8

文献信息

• Phosphate derivatives of diaryl 1,3,4-oxadiazolone
  申请人：Bristol-Myers Squibb Company

  公开号：US05939405A1

  公开（公告）日：1999-08-17

  The present invention provides novel phosphate derivatives having the general formula wherein A, R.sup.1 and R.sup.2 are as defined herein, or a nontoxic pharmaceutically acceptable salt or solvate thereof and are useful in the treatment of disorders which are responsive to the opening of potassium channels.

  本发明提供了具有一般式的新型磷酸盐衍生物，其中A、R^1和R^2如本文所定义，或其无毒的药用可接受盐或溶剂，可用于治疗对钾通道开放有响应的疾病。
• PHOSPHATE DERIVATIVES OF DIARYL 1,3,4-OXADIAZOLONE
  申请人：Bristol-Myers Squibb Company

  公开号：EP1056754B1

  公开（公告）日：2003-10-22
• EP1056754A4
  申请人：——

  公开号：EP1056754A4

  公开（公告）日：2002-03-06
• [EN] PHOSPHATE DERIVATIVES OF DIARYL 1,3,4-OXADIAZOLONE<br/>[FR] DERIVES PHOSPHORIQUES DE DIARYL 1,3,4-OXADIAZOLONE
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：WO1999038873A1

  公开（公告）日：1999-08-05

  (EN) The present invention provides novel phosphate derivatives having general formula (I) wherein A, R1 and R2 are as defined herein, or a nontoxic pharmaceutically acceptable salt or solvate thereof and are useful in the treatment of disorders which are responsive to the opening of potassium channels.(FR) La présente invention concerne de nouveaux dérivés phosphoriques de formule générale (I), dans laquelle A, R1, et R2 sont tels que définis dans l'invention. Cette invention concerne également un sel ou un produit de solvatation non toxiques pharmaceutiquement acceptables de ces composés, pouvant être utiles au traitement des troubles liés à l'ouverture de canaux potassium.